Light Sensitization Study

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01327040
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
32
1
4
122
0.3

Study Details

Study Description

Brief Summary

Circadian rhythm disorders are a class of sleep disorders characterized by misalignment between the timing of sleep and the timing of rhythms driven by the biological clock. Light therapy can effectively treat these disorders, but the intensity and duration of light exposure required to do so has limited its practical use. In this study the investigators will test whether pre-exposure to dim light may enhance the response of the circadian system to light therapy. If so, this could result in shorter treatments that would have greater practical applications.

Condition or Disease Intervention/Treatment Phase
  • Other: light exposure
N/A

Detailed Description

Sleep disorders affect 35-40% of adults, resulting in diminished quality of life, and increased morbidity, mortality, and risk of automobile and occupational accidents. Circadian rhythm sleep disorders form a distinct class of sleep disorders characterized by misalignment between the timing of sleep and the circadian pacemaker. While light therapy can be an effective treatment of circadian rhythm sleep disorders, there are numerous practical limitations.

Light is the most powerful signal from the environment that influences and regulates daily biological rhythms. It is well-established that the irradiance, duration, and timing of light exposure all affect the response of the circadian system. While it was once thought that these responses were mediated through the visual system, it is now known that there is a network of intrinsically photosensitive retinal ganglion cells (ipRGCs) that mediate circadian responses to light. Other new studies have demonstrated that recent light exposure history affects the circadian response to light in humans.

These recent findings have important implications for the use of light to treat circadian rhythm disorders, including delayed and advanced sleep phase disorders, shift work sleep disorder, and jet lag, and they may also have relevance for the use of light to treat seasonal affective disorder. Up to now, little attention has been paid to the duration or intensity of light exposure prior to such light treatments. The investigators now have evidence that the human circadian system can become desensitized to light during long exposures and evidence that it can be sensitized to light by prior exposure to dim light. These recent findings suggest that light treatment protocols that sensitize the circadian system prior to the light treatment will be more effective than those currently in use.

The 13-day inpatient studies the investigators propose will examine the effect on the human circadian system of different durations of dim-light sensitization prior to a standardized light treatment. These results will be compared within subjects in a randomized cross-over design study in which each subject will receive a control treatment and a light treatment with prior dim-light sensitization. The investigators will also include circadian phase disorder patients to test these mechanisms in the target patient population. Our findings will provide an important step in understanding how new knowledge about the circadian photoreceptive system can be used to refine and provide better treatment options for circadian rhythm disorders.

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Sensitization of Human Circadian Responses to Light
Study Start Date :
Oct 1, 2010
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: sensitization duration 1.375h

This group will experience a 1.375h sensitization duration prior to the 12h light exposure

Other: light exposure
12-hour light exposure of approximately 200 lux

Experimental: sensitization duration 5.5h

This group will experience a 5.5h sensitization duration prior to the 12h light exposure

Other: light exposure
12-hour light exposure of approximately 200 lux

Experimental: sensitization duration 22h

This group will experience a 22h sensitization duration prior to the 12h light exposure

Other: light exposure
12-hour light exposure of approximately 200 lux

Experimental: sensitization duration 0.33h

This group will experience a 0.33h sensitization duration prior to the 12h light exposure

Other: light exposure
12-hour light exposure of approximately 200 lux

Outcome Measures

Primary Outcome Measures

  1. circadian phase timing [During inpatient study, on days 6-7 and 11-12]

    timing of circadian phase as assessed using melatonin and temperature data

Secondary Outcome Measures

  1. melatonin suppression [During inpatient study, on days 6-7 and 11-12]

    percent of melatonin suppression

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • healthy adults with conventional and regular sleep-wake timing

  • non-smokers

  • completion of medical, psychological, ophthalmological, and sleep screening tests

  • able to spend 13 consecutive days/nights in the laboratory

Exclusion Criteria:
  • history of neurological or psychiatric disorder

  • history of eye injury, eye surgery, or visual disorder (corrective lenses are acceptable)

  • history of sleep disorder or regular use of sleep-promoting medication

  • current prescription, herbal, or over-the-counter medication use (oral contraceptives are acceptable)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brigham and Women's Hospital Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Brigham and Women's Hospital
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Charles A Czeisler, PhD, MD, Brigham and Women's Hospital
  • Study Director: Jeanne F Duffy, PhD, Brigham and Women's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jeanne Duffy, Associate Neuroscientist, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01327040
Other Study ID Numbers:
  • 2010-P-000346
  • R01HL094654
First Posted:
Apr 1, 2011
Last Update Posted:
Jul 1, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Jeanne Duffy, Associate Neuroscientist, Brigham and Women's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 1, 2021